ISSN 2564-7784 | E-ISSN 2564-7040
Original Article
Polyclonal Antibody Production against Hapten Structured KDN Molecule by Using Different Adjuvants Alternative to Freund's Adjuvant
1 Department of Bioengineering, Ege University School of Medicine, İzmir, Turkey  
Eur J Ther ; : -
DOI: 10.5152/EurJTher.2018.400
Key Words: KDN (2-keto-3-deoxy-D-glycero-D-galacto-nononic acid), polyclonal antibody, montanide
Abstract

 

Objective: KDN (2-keto-3-deoxy-D-glycero-D-galacto-nononic acid), member of sialic acid family, is a hapten structured low molecular weight monosaccharide on the cell membrane, cannot have immunogenic properties without a carrier protein. Since it is overexpressed in cancerous cells, it is thought to be a target molecule for anti-cancer treatments. The aim in this study is to obtain a high titre anti-KDN response without using any carrier protein against the hapten structured KDN molecule to alternative for Freund's adjuvants.

 

Methods: Montanide™ ISA 61 VG which is a water-in-oil adjuvant; ISA 201 VG which is a water-in-oil-in-water emulsion adjuvant and IMS 1313 VG NPR which is an aqueous dispersion based nanoparticle (50-200 nm) micro emulsion adjuvant and Freund's adjuvant were used as anti-KDN antibody response stimulators. Four Balb/c mice were used for each adjuvant group and immunization was performed at eight different time points. Anti-KDN antibody levels induced after each immunization with different adjuvants were detected with indirect Enzyme-Linked Immunosorbent Assay (ELISA).

 

Results: The adjuvant efficiency of Montanide ISA 61 VG was 1.4 times higher than Freund's adjuvant (p <0.0001) with maximum anti-KDN level on day 83.

 

Conclusion: It was concluded that higher amount anti-KDN antibody titers could be obtained by using more safe and effective Montanide ISA 61 VG adjuvant as an alternative to Freund's adjuvants, without any carrier protein conjugation of molecule such as hapten structured KDN. In this regard, it may be possible to produce high antibody titres without using any carrier molecule, especially when commercial large scale monoclonal antibodies are desired to be produced against haptens.

Key Words
Authors
All
Survey
AVES | Copyright © 2018 European Journal of Therapeutics | Latest Update: 30.03.2018